دورية أكاديمية

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?

التفاصيل البيبلوغرافية
العنوان: Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
المؤلفون: Vergori A., Gagliardini R., Gianotti N., Gori A., Lichtner M., Saracino A., De Vito A., Cascio A., Di Biagio A., Monforte A. D., Antinori A., Cozzi-Lepri A.
المساهمون: Vergori A., Gagliardini R., Gianotti N., Gori A., Lichtner M., Saracino A., De Vito A., Cascio A., Di Biagio A., Monforte A.D., Antinori A., Cozzi-Lepri A.
بيانات النشر: Elsevier B.V.
سنة النشر: 2020
المجموعة: IRIS Università degli Studi di Palermo
مصطلحات موضوعية: Antiretroviral therapy, Dual therapy, eGFR, HIV, Tenofovir alafenamide, Tenofovir disoproxil fumarate
الوصف: Our aim was to evaluate the association between recent eGFR values and risk of switching from TDF to TAF or dual therapy (DT) in real life. HIV-positive patients achieving HIV-RNA ≤50 copies/mL for the first time after starting a TDF-based regimen were included. Kaplan–Meier (KM) curves and Cox regression models were used to estimate the time from TDF to switch to TAF or DT. 1486 participants were included: median (IQR) age 36 (30–42) years; baseline CKD-EPI eGFR 99.92 (86.47–111.4) mL/min/1.73m2. We observed a consistently higher proportion of people with HIV-RNA ≤50 copies/mL who switched from TDF to TAF rather than to DT. By competing risk analysis, at 2 years from baseline, the probability of switching was 3.5% (95% CI 2.6–4.7%) to DT and 46.7% (42.8–48.5%) to TAF. A significantly higher probability of switching to TAF was found for patients receiving INSTI at baseline versus NNRTIs and PI/b [KM, 65.6% (61.7–69.4%) vs. 4.0% (1.8–6.1%) and 59.9% (52.7–67.2%), respectively; P < 0.0001]. eGFR <60 mL/min/1.73m2 both as time-fixed covariate at baseline or as current value was associated with a higher risk of switching to DT [aHR 6.68 (2.69–16.60) and 8.18 (3.54–18.90); P < 0.001] but not to TAF-based cART [aHR 0.94 (0.39–2.31), P = 0.897; and 1.19 (0.60–2.38), P = 0.617]. Counter to our original hypothesis, current eGFR is used by clinicians to guide switches to DT but does not appear to be a key determinant for switching to TAF.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32919008; info:eu-repo/semantics/altIdentifier/wos/WOS:000596387600037; volume:56; issue:6; numberofpages:10; journal:INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS; http://hdl.handle.net/10447/510196Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85091710501
DOI: 10.1016/j.ijantimicag.2020.106154
الإتاحة: https://doi.org/10.1016/j.ijantimicag.2020.106154Test
http://hdl.handle.net/10447/510196Test
حقوق: info:eu-repo/semantics/closedAccess
رقم الانضمام: edsbas.88960682
قاعدة البيانات: BASE